Stay updated with breaking news from Upfront Payment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF...
The telecommunications landscape in the United States is fiercely competitive, and choosing between Mint Mobile and T-Mobile can be a challenging decision.
REGINA, Saskatchewan, Nov. 07, 2023 (GLOBE NEWSWIRE) — Information Services Corporation (TSX:ISV) (“ISC” or the “Company”) today reported on the Company’s…
Bristol Myers Squibb has acquired Orum Therapeutics' experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday. The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration's (FDA) clearance for an early stage study. The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.
TOKYO (Reuters) -Japan's Daiichi Sankyo announced on Friday a $5.5 billion agreement with Merck to jointly develop its three precision cancer drug candidates, in a deal that could generate $16 billion more depending on their success. All three candidates belong to the class of drugs known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors. Unlike conventional chemotherapy, which can kill healthy cells, ADCs are de